Journal of Psychopharmacology
July 31, 2024
Roman Palitsky, Deanna M. Kaplan, John Perna et al.
32 citations
A multidisciplinary working group identified 54 potential adverse events that warrant systematic assessment in psychedelic-assisted therapies, finding that existing measurement tools substantially fail to cover these constructs. The group developed recommendations for when and how to assess these adverse events across preparation, dosing, integration, and follow-up phases, and demonstrated a preliminary assessment protocol. The framework addresses the need to capture post-acute dosing adverse events, accounting for both the pharmacotherapy and psychotherapy components of psychedelic-assisted therapy, as well as documented impacts on worldviews and spirituality.
BMC Psychiatry
February 28, 2025
John Perna, Justin Trop, Roman Palitsky et al.
15 citations
A case report describes tensions between legal and underground psychedelic use within therapy training programs, psychiatry, and neo-shamanism. It details how psychiatric interventions like electroconvulsive therapy and energy medicine were used to address prolonged adverse effects from psychedelics. The report urges clinicians to recognize conflicts between psychiatric views of these adverse effects and frameworks in psychedelic communities, which can affect patients' symptoms, decisions, and emotional struggles.
Psychedelics.
December 17, 2024
Zachary Bosshardt, Jessica L. Maples‐keller, Deanna M. Kaplan et al.
Attendees at a conference on psychedelics and spiritual care generally agreed that microdosing may have benefits and expressed modest concern about potential harm from therapeutic psychedelic use. Among 178 survey respondents, 40.2% agreed or strongly agreed that psychedelics could be harmful therapeutically, while 30.7% were unsure. A subset of 32 psychedelic care facilitators reported using psychedelics to treat a wide range of diagnoses with diverse psychotherapy approaches and endorsed a need for cultural adaptations in psychedelic treatments.